脑脊液神经元五聚素受体作为阿尔茨海默病长期进展的生物标志物：一项 24 个月随访研究。

Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer's disease: a 24-month follow-up study.

机构信息

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.

Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway; Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.

出版信息

Neurobiol Aging. 2020 Sep;93:97.e1-97.e7. doi: 10.1016/j.neurobiolaging.2020.03.013. Epub 2020 Mar 31.

DOI:10.1016/j.neurobiolaging.2020.03.013

PMID:32362369

Abstract

Lower cerebrospinal fluid (CSF) levels of neuronal pentraxin receptor (NPTXR) are associated with Alzheimer's disease (AD), but few studies show longitudinal changes in CSF NPTXR. In the present study, CSF NPTXR was measured at 0, 12, and 24 months using an enzyme-linked immunosorbent assay. The study groups included 28 patients with mild cognitive impairment (MCI) (MCI-MCI), 27 MCI patients who progressed to AD (MCI-AD) during the study, and 28 AD patients (AD-AD). Baseline levels were assessed for 46 control individuals. AD patients had lower baseline CSF NPTXR than controls (p = 0.023). Linear mixed models estimated a 6.7% annualized decrease in CSF NPTXR in the AD-AD group, significantly different from MCI-MCI (p = 0.03) and MCI-AD groups (p = 0.048). CSF NPTXR did not correlate with CSF Aβ42 and weakly correlated with CSF Aβ40, T-tau, P-tau (all R < 0.22, p < 0.06). These trends suggest CSF NPTXR may be a candidate biomarker of AD progression but not sufficiently sensitive to resolve when patients convert from MCI to dementia.

摘要

脑脊液（CSF）中神经元五聚素受体（NPTXR）水平降低与阿尔茨海默病（AD）有关，但很少有研究显示 CSF NPTXR 的纵向变化。在本研究中，使用酶联免疫吸附测定法在 0、12 和 24 个月时测量 CSF NPTXR。研究组包括 28 名轻度认知障碍（MCI）患者（MCI-MCI）、27 名在研究期间进展为 AD 的 MCI 患者（MCI-AD）和 28 名 AD 患者（AD-AD）。对 46 名对照个体进行了基线水平评估。AD 患者的基线 CSF NPTXR 低于对照组（p=0.023）。线性混合模型估计 AD-AD 组 CSF NPTXR 的年化下降率为 6.7%，与 MCI-MCI 组（p=0.03）和 MCI-AD 组（p=0.048）差异显著。CSF NPTXR 与 CSF Aβ42 不相关，与 CSF Aβ40、T-tau、P-tau 弱相关（所有 R<0.22，p<0.06）。这些趋势表明 CSF NPTXR 可能是 AD 进展的候选生物标志物，但不足以敏感地分辨出从 MCI 转化为痴呆的患者。